The average one-year price target for Aurobindo Pharma (NSEI:AUROPHARMA) has been revised to 1,148.79 / share. This is an increase of 9.32% from the prior estimate of 1,050.84 dated January 16, 2024.

Aurobindo Pharma is clearly at an inflection point as the company pivots into complex modalities like Pen-G, biologics CMO and biosimilars.

Aurobindo Pharma’s fair value estimate has been revised from ₹1,379.96 to ₹1,519.97, giving investors an updated anchor for ...

Choice Broking said that Delhivery is showing strong bullish momentum after delivering a decisive breakout above a key horizontal resistance level, indicating a continuation of the uptrend.

ICICI Securities has downgraded Aurobindo Pharma to Add (from Buy earlier) with a revised target price of Rs 1,330 (earlier Rs 1,445). The current market price of Aurobindo Pharma Ltd. is Rs 1147.95.

Pharma major reports 2 per cent rise in profit to Rs 920.84 crore and 5.6 per cent growth in revenue to Rs 8,853.34 crore, ...

Indian pharma is entering its next growth phase as a new segment gains traction. We analyse four companies building this ...

Tata Technologies (₹747): The trend is down ever since the stock got listed in November 2023.The strong rise from the low of ₹507.50 made in March will still be a correction within the broad downtrend ...

Aurobindo Pharma said the US FDA completed a pre-approval inspection at Eugia Steriles’ Andhra Pradesh facility between June 10 and June 19, 2026. The inspection concluded with five observations, ...